Relay Therapeutics is a cash-burning clinical-stage biotech with a single lead asset (zovegalisib) that currently trades well below analyst price targets, but pipeline concentration and weak business fundamentals make this a speculative holding requiring clear clinical progress to justify the premium.
Thesis pillars
- Options Market Bearish Signal↓Deteriorating
- Pipeline Concentration Single Asset↓Deteriorating
- Quality Floor Failure Cash Burn→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026
Relay Therapeutics, Inc. (RLAY) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $19.69: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 23%; Elevated put/call ratio: 2.34; Below-average business quality.
Relay Therapeutics develops small molecule precision medicines for cancer and genetic disease using its Dynamo® platform for motion-based drug discovery, with no approved products and no commercial revenue. The lead candidate, zovegalisib (RLY-2608), an allosteric PI3Kα... Read more
Sell if holding. Engine safety override at $19.69: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 23%; Elevated put/call ratio: 2.34; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Score 4.3/10, moderate confidence.
Passes 5/7 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on clean insider activity and earnings proximity 6d<=7d. Suitability: speculative.
About Relay Therapeutics, Inc.
About Relay Therapeutics, Inc.
Relay Therapeutics advanced zovegalisib into the Phase 3 ReDiscover-2 Trial in Q2 2025, targeting PI3Kα-mutated HR+/HER2- breast cancer patients previously treated with a CDK4/6 inhibitor, with 540 patients randomized against capivasertib plus fulvestrant. The estimated addressable population totals approximately 140,000 patients annually in the U.S. In February 2026, the FDA granted Breakthrough Therapy designation to the zovegalisib-plus-fulvestrant combination, a regulatory milestone that provides more intensive FDA guidance and review.
Relay generates no commercial revenue; the company funds operations through capital markets and its balance sheet. Zovegalisib is the sole compound in late-stage development; two earlier-stage candidates — NRAS inhibitor RLY-8161 and a non-inhibitory chaperone for Fabry disease — remain in preclinical or early clinical stages. The Dynamo platform uses cryo-EM structures and long-timescale molecular dynamics simulations to identify allosteric pockets in target proteins, differentiating its approach from orthosteric PI3Kα inhibitors such as alpelisib and capivasertib, which carry high rates of severe hyperglycemia. In June 2024, Relay entered a global clinical trial collaboration with Pfizer to evaluate zovegalisib in combination with fulvestrant and atirmociclib — Pfizer's selective-CDK4 inhibitor — in PI3Kα-mutated metastatic breast cancer. In December 2024, the company licensed lirafugratinib (RLY-4008) to Elevar Therapeutics under an exclusive global agreement, removing the FGFR2 inhibitor from the company's P&L while preserving the zovegalisib franchise.
Show full overview
Pipeline binary risk dominates Relay's investment profile. The Phase 3 ReDiscover-2 Trial is enrolling 540 patients with no primary endpoint data expected until the study matures. Interim data from the Phase 1/2 ReDiscover Trial as of October 15, 2025 showed a 39% objective response rate and 10.3-month median PFS in the key efficacy subset, but these are Phase 1/2 results; the Phase 3 comparator (capivasertib plus fulvestrant) is an approved regimen. If ReDiscover-2 fails to demonstrate superiority, the company's entire commercial pipeline could be at risk.
See also: Healthcare · Biotechnology
From Relay Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-29Recent Developments — Relay Therapeutics, Inc.
Latest news
- NEWS Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026 — fiscal.ai Oct 28, 2026 neutral
- NEWS HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29 — benzinga Aug 20, 2026 positive
- NEWS JP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31 — benzinga Aug 14, 2026 positive
- NEWS Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26 — benzinga Aug 10, 2026 positive
- NEWS Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30 — benzinga Aug 7, 2026 positive
Generated 2026-10-29T11:48:40Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinezovegalisib (RLY-2608)10-K Item 1: 'zovegalisib (RLY-2608), our lead product candidate ... we initiated a global Phase 3 registrational study, or the ReDiscover-2 Trial'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers
Revenue shrinking — -48.3% YoY. Growth thesis broken unless recovery story develops.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $19.69: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 23%; Elevated put/call ratio: 2.34; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Prior stop was $18.31. Score 4.3/10, moderate confidence.
Analyst target: $24.00 (+21.9% upside). Prior stop was $18.31. Stop-loss: $18.31.
Concentration risk — Pipeline: zovegalisib (RLY-2608); Quality below floor (1.5 < 4.0); Value-trap signals (2/5): Margin compression (op margin -62.9%), Material insider selling (8 sells, 3.50% of cap).
Relay Therapeutics, Inc. trades at a P/E of N/A (forward -12.1). TrendMatrix value score: 7.5/10. Verdict: Sell.
19 analysts cover RLAY with a consensus score of 4.3/5. Average price target: $28.
What does Relay Therapeutics, Inc. do?Relay Therapeutics develops small molecule precision medicines for cancer and genetic disease using its Dynamo®...
Relay Therapeutics develops small molecule precision medicines for cancer and genetic disease using its Dynamo® platform for motion-based drug discovery, with no approved products and no commercial revenue. The lead candidate, zovegalisib (RLY-2608), an allosteric PI3Kα inhibitor, entered a Phase 3 trial in Q2 2025 for HR+/HER2- breast cancer and received FDA Breakthrough Therapy designation in February 2026.